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Background: Acne is a very common skin condition during adolescence and adulthood. Patients with uterovaginal
agenesis (Mayer-Rokitansky-Küster-Hauser syndrome, MRKH) treated at the Tübingen University Center for Rare
Female Genital Malformations, however, clinically appeared to be less frequently affected by acne. The etiology of
MRKH syndrome remains unknown. The only known MRKH-associated mutations are located within the WNT4 gene
and lead to an atypical form of MRKH syndrome associated with clinical and biochemical hyperandrogenism. Our
study aimed to assess the frequency, severity, and self-evaluation of acne in MRKH patients and to correlate the
clinical findings with hormone analyses.
Methods: As part of a cross-sectional longterm follow-up study after laparoscopic assisted creation of a neovagina
a questionnaire was sent to 149 MRKH patients aged 16–44 years comprising 26 items concerning prevalence and
self-evaluation of acne, and the effects of acne on quality of life. The questionnaire was derived from one used in a
former epidemiological study of acne in 4,000 women. Blood for hormone analyses was collected routinely during
the clinical visit.
Results: Fully completed, evaluable questionnaires were returned by 69/149 (46%) women. Of these respondents,
42 (60.1%) showed hyperandrogenemia without other clinical signs of virilization but only 17 (24.6%) reported acne
(8 (11.6%) had physiological acne and 9 (13.0%) clinical acne) and only 10 (14.5%) reported receiving medical
treatment for their acne. Effects of acne on quality of life were minor. Only 4 patients (5.8%) with PCOS were
identified, among them one with physiological acne, the other three within the acne-free group.
Conclusions: Although hyperandrogenemia is common, acne is significantly less frequent in women with MRKH
than reported in the literature for non-MRKH women, and is seldom treated medically. Patients in this study
appeared resistant to acne to some extent, possibly due to the sebaceous glands in the acne regions being less
sensitive to androgens compared to the normal population. A WNT4 mutation is unlikely to be the main cause of
MRKH syndrome in our hyperandrogenemic patients.
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Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome is
characterized by congenital uterovaginal agenesis [1,2],
resulting from cessation of müllerian duct development
around the fifth week of gestation [3]. The incidence of
MRKH syndrome is estimated at 1 in 4,500 female births
[4]. Despite ongoing research, the etiology of this syn-
drome has begun to be elucidated for some women, but
is still unknown for the majority of patients.
Since women with the syndrome have a normal 46,XX
karyotype and functioning ovaries, they show normal
physical development and manifestation of secondary se-
xual characteristics [1,2]. Compared to controls, MRKH
patients are generally similar in hormone levels and can
be grouped into cyclic phases [4-6]. In the majority of
cases there are no clinical or biochemical signs of hype-
randrogenism [2].
Due to familial clustering, the possibility of genetic
causes has been the subject of continued study. MRKH
syndrome does not present with clearly identifiable ge-
netic causes except in a Wnt4-associated atypical form
with clinical and biological signs of hyperandrogenism
[7]. In mice, the Wnt4 gene regulates female reproduc-
tive tract development and antagonizes testosterone pro-
duction [8]. The WNT4 mutation has been reported to
be associated with failure of müllerian duct formation
and virilization, including acne, in at least four 46,XX
women [9,10]. In fact, it appears that, at least in a sub-
group of MRKH patients, the absence of the vagina and
uterus and excess androgen levels are the pathogno-
monic signs of WNT4 defects, causing a clinical entity
distinct from the typical MRKH syndrome [11,12].
At our Center for Rare Female Genital Malformations,
a joint division of the Department of Gynecology and
the Treatment and Research Center for Rare Diseases at
the University of Tübingen, we provide in close collabo-
ration with the Division of Psychosomatic Medicine at
our university hospital medical treatment, psychological
counseling, and postsurgical follow-up examinations to
more than 40 MRKH patients per year [13].
Acne vulgaris is the most common skin disease world-
wide. Various recent epidemiological studies undertaken
in recent years have shown that acne is very common in
women from mid-to- late adolescence, as well as during
adulthood [14-16]. Primarily a disease of adolescence,
acne is triggered by the initiation of adrenal and gonadal
androgen production and usually subsides after the end
of growth [16-18]. At our institution, MRKH patients
appeared to have less acne than expected during routine
follow-up, despite being in the predisposed age group.
Acting as an endocrine organ, the sebaceous gland re-
sponds to changes in androgens and other hormones
[19,20]. Although levels of circulating androgens are
mostly normal, sebaceous glands in acne regions aremore sensitive to androgens than in other parts of the
body [21].
There is a genetic predisposition to acne. However, the
specific mechanisms of inheritance remain unclear [22,23].
There are two main assessment aspects, the first being
the objective activity of the disease (visible signs) and
the second being its impact on quality of life. Although
more than 25 different methods have been developed
to measure acne, it remains difficult to do so objectively
because there is no general agreement as to the most
suitable method [19].
Polycystic ovary syndrome (PCOS) is a reproductive
and metabolic disorder affecting 5-10% of women in
their reproductive age [24]. A refined definition of PCOS
was agreed, namely the presence of two of the following
three features: oligo- and/or anovulation, which can be
hardly determined in MRKH syndrome, hyperandro-
genism, and polycystic ovaries [25]. An increased pre-
valence of PCOS and Müllerian anomalies has already
been described [26].
The aim of the present study was to determine the fre-
quency, severity and self-evaluation of acne in women
with MRKH and to investigate the potential relationship
between clinical and biochemical signs of androgen ex-
cess including the prevalence of PCOS. A potential cor-
relation between MRKH and reduced acne prevalence
may contribute to a better understanding of the etiology
of MRKH syndrome, especially with respect to the role
of the Wnt signaling cascade.
Methods
Study design and participants
This was part of a cross-sectional study in which a ques-
tionnaire was sent out by postal mail in April 2010 to 149
women with MRKH syndrome treated at the Centre for
Rare Genital Malformations, a division of the Department
of Obstetrics and Gynecology at Tübingen University
Hospital, Germany, as a longterm follow-up after laparo-
scopic assisted creation of a neovagina. The primary aim
of this part of the study was to assess the presence of
clinical acne, physiological acne, or no acne. We received
prior approval from the Ethics Committee of Tübingen
University Hospital.
Patients included in the study had proven MRKH syn-
drome, a normal female 46,XX karyotype, normal pubertal
development, and normal secondary sexual characteristics.
There were no patients with clitoral hypertrophy or hir-
sutism. Hormonal work-up (normal ranges) included total
testosterone (<0.35–1.4 nmol/L below 21 years of age and
0.4–2.1 nmol/L over 21 years), luteinizing hormone (0.5–
76.3 IU/L), follicle-stimulating hormone (1.5–33.4 IU/L),
androstenedione (1.17–12 nmol/L), dehydroepiandro-
sterone sulfate (DHEAS; 0.8–11.5 umol/L), progesterone
(16–2000 nmol/L), estradiol (70–1300 pmol/L) and 17-
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androgenemia was defined as elevated testosterone levels
with or without elevated androstenedione, 17-OHP, and/or
DHEAS levels.
The incidence of polycystic ovary syndrome (PCOS)
was determined by evaluation of the routinely performed
ultrasound, pelvic magnetic resonance imaging (MRI) as
well as by analyzing the surgical reports.Questionnaire
The questionnaire comprised 26 items and was based on
a French questionnaire used in a 2001 epidemiological
survey of acne in 3,394 adult women aged 25–40 years
[16]. The original French questionnaire was validated
and contained 40 questions relating to skin type, life-
style, factors influencing or preventing acne, current skin
care practices, and the effect of acne lesions on qua-
lity of life (Dermatology Life Quality Index (DLQI) [27].
The original French questionnaire was translated into
German by a native German dermatologist and validated
through back translation by a native French and German
speaker (see Additional file 1). To assess quality of life,
the questionnaire was complemented with the German
version of the Finlay DLQI questionnaire, used with kind
permission of Dr. M. Basra, Department of Dermatology,
Cardiff University [28].
Essentially, participants were asked whether they had
had acne between the ages of 12 and 20 years and also
whether they had had acne after age 20 years. They were
also asked to count the number of currently active pus-
tules, papulonodules, blackheads and closed comedones




Respondents returning evaluable questionnaires, n
Demographic and clinical characteristics
Mean age ± SD, years (n = 69) 23.6
Median age [range], years (n = 69) 21.0
Inflamed lesions (at date of questionnaire), mean no.
Inflamed lesions (at date of questionnaire), median no. [range] 6 [
Medical treatment for acne, n
Androgen status
Hyperandrogenemia, n (%*) 6 (1
No hyperandrogenemia, n (%*) 2 (1
Incomplete hormonal work-up, n (%*) 1 (
— no data.
n.a. not applicable.
*percent of row total.Acne severity was categorized “clinical acne”, “physio-
logical acne” or “no acne” according to a clinical index
modified from [16]. The main modification consisted in
limiting the information requested to the date of the
questionnaire rather than covering the prior 3-month
period. Thus, the following definitions were used:
 Clinical acne: ≥ 5 pustules or papulonodules on the
face (except nose) with or without blackheads at the
date of the questionnaire, or > 2 pustules or
papulonodules on the face (except nose) with
blackheads at the date of the questionnaire
 Physiological acne: 1 or 2 pustules or papulonodules
on the face (except nose) with or without
blackheads at the date of the questionnaire
 No acne: no pustules or papulonodules, and no
blackheads at the date of the questionnaire.
Statistical analysis
Statistical analysis was performed using SPSS software
version 17.0. The Kruskal-Wallis test was used to compare
MRKH patients with and without acne for differences in
risk factors. Spearman’s rho was used to correlate acne
severity and effects on quality of life. The chi-square test
was used to detect significant differences in acne preva-
lence between women with and without MRKH syndrome




The demographic and clinical characteristics of the study
cohort are summarized in Table 1.ionnaire survey on acne
al acne Physiological acne No acne All respondents
— — — 149
— — — 71
9 8 52 69
± 6.6 23.1 ± 5,3 23.3 ± 6.6 23.3 ± 6.4
[18-39] 21.5 [17-33] 21.0 [16-44] 21.0 [16-44]
7.8 1.9 n.a. n.a.
3-17] 2 [1-3] n.a. n.a.
1 0 9 10
4.3%) 6 (14.3%) 30 (71.4%) 42 (100%)
4.3%) 0 (0%) 12 (85.7%) 14 (100%)
7.7%) 2 (15.4%) 10 (76.9%) 13 (100%)
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149 invited MRKH women had responded. Of the other
78 women, 3 had declined to participate in the survey,
and 19 had not received their questionnaires as these
were returned as undeliverable.
Of the 71 questionnaires returned, 69 were evaluable
whilst 2 were incomplete. Respondents were 16–44 (mean
23.3, median 21.0) years of age. 31 patients had associated
malformations, mainly of the kidneys and skeletal system.
Acne prevalence and severity
Of the 69 evaluable respondents, 52 (75.4%) reported
being free of acne at the date of questionnaire completion.
The remaining 17/69 (24.6%) women reported having
acne, which was categorized as clinical acne in 9/69
(13.0%) and as physiological acne in 8/69 (11.6%) women.
The acne severity score, as determined by counting spe-
cific skin lesions, tended to be slightly higher in MRKH
patients compared to other acne patients from the litera-
ture. The ratio between clinical and physiological acne
was nearly 1:1. Thus about 50% of our respondents
affected by acne had physiological acne. There was no
correlation between hyperandrogenemia or acne (Table 1)
and a more severe MRKH phenotype with associated
malformations.
MRKH women with clinical acne on the cheeks mainly
had blackheads. Pustules were present on the forehead
but completely missing from the chin and nose. Papu-
lonodules occurred predominantly on the chin, while
closed comedones occurred predominantly on the nose.
In the women with clinical acne, the mean number of
inflamed lesions at the date of the questionnaire was 7.8
(median [range], 6 [3-17]) whilst it was 1.9 (2 [1-3]) in
those with physiological acne (Table 1).
All MRKH women with clinically overt clinical acne and
physiological acne reported manipulating (squeezing) their
lesions.
Out of the 7 participants aged ≥21 years with clinical
acne, 2 (29%) had not had acne during their teens. Com-
bining clinical and physiological acne, 3 out of 13 women
(23%) had not had acne during their teens.
Risk and stress factors, e.g. smoking, quality of sleep and
use of make-up were also investigated. A Kruskal-Wallis
test showed that MRKH women with acne did not differ
significantly from MRKH women without acne in respect
of daily cigarette consumption, quality of sleep and use of
make-up.
Treatment
Only 10 (14%) out of all 69 evaluable respondents re-
ported receiving medical treatment for their acne lesions
(Table 1). One of the 9 (11.1%) respondents with clinical
acne and none of the 8 (0%) respondents with physio-
logical acne reported having received such treatment. Ofthe 52 women who reported being acne-free, 9 (17%)
had received medical treatment for their acne, of whom
4 (44%) reported having had clinical acne between the
age of 12 and 20.
The following concomitant medications were re-
ported: hormonal contraceptives, 3/69 (4%); other sys-
temic hormones, 3/69 (4%); topical estrogen cream in
the genital area for other reasons, 2/69 (3%); and anti-
biotics, 5/69 (7%).
Hyperandrogenemia
The results of the hormonal work-up are shown by acne
category in Table 1. As many as 42/69 (60.1%) showed
hyperandrogenemia without other clinical signs of viri-
lization. Serum testosterone levels ranged between 1.5 and
4.0 nmol/L. Of the acne-free women, 30/52 (57.7%) had
biochemical signs of hyperandrogenism, 12/52 (23.1%)
had normal results, and 10/52 (19.2%) only had an incom-
plete hormonal work-up. Hyperandogenemia was present
in 6 (75%, 2 unknown) patients with physiological acne
and 6 patients (66.7%, 1 unknown) with clinical acne. Nor-
mal androgen levels were observed in 2 (22.2%) of the 9
patients with clinical acne and none of the patients with
physiological acne.
Prevalence of PCOS
Evaluating ultrasounds and pelvic MRIs and retrospect-
ive analysis of the surgical reports identified only 4 pa-
tients (5.8%) with PCOS. Among them was one with
physiological acne, the other three were within the acne-
free group, in 6 patients the morphology of the ovaries
was unknown, while in 59 patients (85.5%) the criteria
for polycystic ovaries were not met.
Quality of life
The DLQI was used to investigate the relationship bet-
ween quality of life and severity of acne. Results ranged
from “no alteration” to “moderate reduction”. There was a
significant difference between the groups with “clinical
acne”, “physiological acne”, and “no acne” (F (2.65) =
6.591, p = 0.002). Post-hoc tests showed that the “clinical
acne” group (mean score ± standard deviation (SD) 3.76 ±
2.50, n = 9) differed significantly from both the “no acne”
group (1.25 ± 1.91, n = 52; p = 0.003) and the “physio-
logical acne” group (0.88 ± 0.99, n = 8; p = 0.011). There
was no significant difference between the “no acne” and
“physiological acne” groups (p = 0.861, see Figure 1).
Despite the high percentage of hyperandrogenemia the
chi-square test showed that at 24.6% (17 of 69 respon-
dents), the prevalence of acne in the adolescent and adult
women with MRKH participating in our study was signifi-
cantly lower than in comparable cohorts of women and
girls without MRKH, for example in Iranian adolescents
(acne prevalence 92%, p <0.0001) [14], adolescents in
Figure 1 Effect of clinically overt acne lesions on quality of life. Analysis by category of self-reported acne severity using the Dermatology
Life Quality Index (DLQI) (according to [16]).
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French adolescents (acne prevalence 41%, p =0.04) [16].
Discussion
This is the first study to report an unexpectedly low rate
of clinical signs of androgen excess in a sample of 69
women with MRKH syndrome, as many as 60.8% of which
had biochemical hyperandrogenemia. Androgen excess is
one of the most common endocrinopathies, affecting ap-
proximately 7% of reproductive-aged women, the majority
with a diagnosis of polycystic ovary syndrome (PCOS) and
both clinical and biochemical evidence of hyperandrogen-
ism. Clinically, hyperandrogenism manifests primarily as
acne, androgenetic hair loss, and hirsutism. However, an
element of observer bias in the evaluation of signs of hir-
sutism and clinical hyperandrogenism has been discussed
in this context [29-32].
Interestingly, acne as a clinical sign of androgen excess
was reported only by 12 (28.6%) of the 42 hyperandro-
genemic women amongst the 69 respondents in our study.
No other signs of hyperandrogenism were observed. The
incidence of PCOS in our patients was not higher than
described in the general population [24]. While nearly all
cases of WNT4 mutations reported in the literature to
date had clinical and biochemical signs of androgen excess
as pathognomonic signs [8-12], these signs were not seen
in our cohort. There was also no correlation between
MRKH syndrome with associated malformations and
hyperandrogenemia or acne. Recent data suggest that
WNT4 mutations cause specific regulation of androgen
synthesis enzymes. Thus, according to one study, the ab-
sence of a WNT4 mutation in four adolescent girls with
MRKH syndrome and clinical and biochemical hyperan-
drogenism strongly suggests the potential involvement
of other constituents of the Wnt4/β-catenin signalingpathway [10]. We therefore conclude that a WNT4 muta-
tion is unlikely to be the cause of MRKH syndrome in the
majority of our hyperandrogenemic patients.
According to many epidemiological studies evaluating
current skin status in adolescents, acne prevalence ranges
between 80% more than 90% [14,15,33]. Two studies
reported mean prevalence in adults as 31.9% and 54%
[17,34]. Considering that our survey included MRKH
women aged 16 to 44, acne prevalence would have been
expected to be much higher than the 24.6% observed in
this study. Despite the high percentage of hyperandro-
genemia the chi-square test showed that at 24.6%, the
prevalence of acne in the adolescent and adult women
with MRKH participating in our study was significantly
lower than in comparable cohorts of women and girls
without MRKH [14-16].
Thus about 50% of our respondents affected by acne
had physiological acne, whereas other studies have re-
ported higher percentages of physiological acne [16,35].
On the other hand, compared to the French study by
Poli et al. [16], we found that the severity score including
counted skin lesions was an average 1.6 points and 1.3
points higher in our patients with clinical and physio-
logical acne, respectively.
Medical treatment of acne was infrequent and non-
specific in our sample of MRKH women. Only 4% of all
women took oral contraceptives, which are associated
with a significantly lower prevalence of acne. Oral contra-
ceptives may modify the androgenic effect and thus in-
fluence both the prevalence and severity of acne [36,37].
Whereas 55% of adolescents aged 14–19 years [38] and
one third of all fertile women in Germany use oral contra-
ceptives, the percentage of MRKH patients taking oral
contraceptives is very low, this being due to infertility. In
view of this, one would have expected acne to be even
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oral contraceptives are effective in treating acne and can
be considered a preventive treatment. Paradoxically, the
highest percentage of acne treatment in our study was
found in the respondents without acne. One possible ex-
planation for this finding could be that these women had
had acne at some time and had been treated successfully.
Analysis of the questionnaire results did not reveal any
correlation between risk and stress factors, e.g. nicotine
use, quality of sleep, make-up use, and the prevalence or
severity of acne. The effect of nicotine consumption on
acne has been addressed in various studies. Some found
a positive correlation between the daily number of ciga-
rettes smoked and acne, while in others there was no
correlation [39,40]. According to the Federal Statistical
Office of Germany, the percentage of smokers among 15
to 45–year-old females was 15–30.4% in 2009 [41]. Al-
though our sample of MRKH included 35% smokers,
acne prevalence was far below average.
The menstrual period, presumed to be one of the most
important aggravating factors in acne [42,43], is natu-
rally missing in MRKH. However, women with MRKH
syndrome have functional ovaries and therefore expe-
rience exactly the same cyclic hormone changes as
women without the syndrome but have a low prevalence
of acne. While the acne questionnaire used in our study
did not specifically ask about cyclically recurring symp-
toms, this question was generally addressed at the rou-
tine follow-up visits after neovagina surgery.
With respect to the correlation between quality of life
factors and acne severity, the DLQI indicated only a slight
decrease in quality of life. No respondent reported severe
changes in quality of life. Several studies have reported a
similar degree of “emotional impairment” as reported by
patients with chronic disabling asthma, epilepsy, diabetes,
arthritis [44], or psoriasis [45]. In our study, quality of
life was only mildly to moderately affected by acne, the
highest observed score being 9 out of 30. This relatively
low score may be considered plausible, however, in view
of the great impact on quality of life associated with the
absence of the uterus and vagina and the infertility this
entails.
A limitation of the present study is the low rate of
returned questionnaires. This was likely due in part to
the fact that the MRKH syndrome is a rare condition,
but may partly also be explained by the observation that
women with MRKH tend to avoid constant confronta-
tion with their condition once they have undergone sur-
gical treatment.
As pointed out in the 2012 European evidence-based
(S3) guidelines for the treatment of acne, there are inherent
difficulties in objectively measuring acne. No international
consensus has been reached on a uniform classification
system for acne. However, this diversity and the frequentlack of validation limits the direct comparability of diffe-
rent trials [19,46,47]. Counting acne lesions – particularly
currently inflamed lesions, as in our study – is a wide-
spread and reliable method of classifying acne [48,49].
Further common grading systems, such as the Global
Acne Grading System (GAGS) [50], the Leeds acne gra-
ding system [51], and the German guidelines [52] assess
current skin status but do not consider a patient’s med-
ical history and lifestyle. Therefore our acne definition
also refers exclusively to current skin status. The study
definitions for assessing the presence or absence of acne
were confirmed by high concordance (72%) between
self-assessment (“Do you have acne?”) and the acne
index of current skin status. In contrast, there was only
a 45% agreement between self-assessment and a defi-
nition based on the anamnestic criterion from the French
study by Poli et al. [16] as to the number of pustules or
papulonodules patients had had on their face during the
last three months. The latter study, according to which
the prevalence of acne in French women was 41%, cannot
be directly compared with our study because of the acne
definition used in that study. We used the same clinical
criteria but focused on currently active lesions whereas
the French study additionally covered the acne history of
the preceding three months. However, their question as to
the number of facial pustules or papulonodules occurring
during the preceding three months may have been am-
biguous since “during” can be interpreted cumulatively as
meaning “in total”, or, in terms of prevalence, as “once or
at the same time” within the past 3 months. Adding the
same anamnestic aspects to the current acne definition
used in our study revealed a large discrepancy between
the current skin status and that of the preceding three
months. With 36 out of 55 (65%) women in the acne
group reporting no current acne lesions, this would have
resulted in a cumulative overestimation of previous skin
lesions.
Conclusions
In conclusion, acne appears to be significantly less fre-
quent in women with MRKH syndrome than in women
without the syndrome and is seldom treated medically. To
date the cause of MRKH is unknown. As only 28.6% of
the 60.8% of MRKH women with hyperandrogenemia in
our study had acne as a clinical sign of androgen excess, a
mutation within the WNT4 gene cannot be expected in
the majority of our hyperandrogenemic patients. The
association of MRKH and clinical signs of hyperandrogen-
ism requires further investigation. Further research is
required to elucidate the relationship between MRKH syn-
drome and the low frequency of acne despite the high fre-
quency of hyperandrogenemia in MRKH women. The
syndrome could be related to a genetic aberration, for ex-
ample, a gene mutation that not only causes the MRKH
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ing acne. This aberration could cause androgen resistance
similar to that in complete androgen insensitivity
syndrome.
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